Literature DB >> 15238643

Remission in rheumatoid arthritis: agreement of the disease activity score (DAS28) with the ARA preliminary remission criteria.

J Fransen1, M C W Creemers, P L C M Van Riel.   

Abstract

OBJECTIVE: To determine which cut-off point in the RA disease activity score (DAS28) corresponds to fulfilment of the ARA criteria for clinical remission.
METHODS: The disease activity of patients included in the Nijmegen RA inception cohort was systematically assessed every 3 months. For all visits, a modification of the ARA preliminary criteria for clinical remission was applied and the DAS28 was calculated. Receiver operating characteristic analysis was used to determine the cut-off point with maximum sensitivity and specificity in DAS28 corresponding with fulfilment of the modified ARA criteria.
RESULTS: Three hundred and seventy-eight patients contributed 4378 visits. In 6.5% of the visits four of the five items and in 1.5% all five items of the modified ARA criteria were fulfilled. The optimal cut-off point for the DAS28 that corresponds to fulfilment of the modified ARA criteria was determined to be 2.66.
CONCLUSION: DAS28 <2.6 corresponds to fulfilment of the preliminary ARA criteria for clinical remission in RA.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15238643     DOI: 10.1093/rheumatology/keh297

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  152 in total

1.  Pulmonary involvement in early rheumatoid arthritis patients.

Authors:  Hisham M Habib; Ashraf A Eisa; Waleed R Arafat; Mohamed A Marie
Journal:  Clin Rheumatol       Date:  2010-05-26       Impact factor: 2.980

2.  Efficacy of B cell depletion in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor alpha agents: an open-label observational study.

Authors:  L Brulhart; A Ciurea; A Finckh; A Notter; J M Waldburger; D Kyburz; C Gabay
Journal:  Ann Rheum Dis       Date:  2006-03-15       Impact factor: 19.103

3.  Possible use of miRNAs-146a and -499 expression and their polymorphisms as diagnostic markers for rheumatoid arthritis.

Authors:  Ghada Ayeldeen; Yasser Nassar; Hanan Ahmed; Olfat Shaker; Tamer Gheita
Journal:  Mol Cell Biochem       Date:  2018-04-26       Impact factor: 3.396

4.  Prediction of treatment response to adalimumab: a double-blind placebo-controlled study of circulating microRNA in patients with early rheumatoid arthritis.

Authors:  S B Krintel; C Dehlendorff; M L Hetland; K Hørslev-Petersen; K K Andersen; P Junker; J Pødenphant; T Ellingsen; P Ahlquist; H M Lindegaard; A Linauskas; A Schlemmer; M Y Dam; I Hansen; H C Horn; A Jørgensen; J Raun; C G Ammitzbøll; M Østergaard; K Stengaard-Pedersen; J S Johansen
Journal:  Pharmacogenomics J       Date:  2015-05-05       Impact factor: 3.550

5.  [Austrian expert opinion on the standard for expert assessment of course of illness in patients with chronic polyarthritis (rheumatoid arthritis)].

Authors:  Klaus P Machold; Hans Peter Brezinsek; Burkhard F Leeb; Stephan Pflugbeil; Franz Rainer; Franz Singer; Martin Skoumal; Tanja A Stamm; Manfred Herold
Journal:  Wien Klin Wochenschr       Date:  2008       Impact factor: 1.704

6.  The good EULAR response at the first year is strongly predictive of clinical remission in rheumatoid arthritis: results from the TARAC cohort.

Authors:  Budsakorn Darawankul; Sumapa Chaiamnuay; Rattapol Pakchotanon; Paijit Asavatanabodee; Pongthorn Narongroeknawin
Journal:  Clin Rheumatol       Date:  2014-07-26       Impact factor: 2.980

7.  Presence of power Doppler synovitis in rheumatoid arthritis patients with synthetic and/or biological disease-modifying anti-rheumatic drug-induced clinical remission: experience from a Chinese cohort.

Authors:  Yan Geng; Jingjing Han; Xuerong Deng; Zhuoli Zhang
Journal:  Clin Rheumatol       Date:  2014-04-29       Impact factor: 2.980

8.  (1)H NMR-based metabolomic analysis for identifying serum biomarkers to evaluate methotrexate treatment in patients with early rheumatoid arthritis.

Authors:  Zhigang Wang; Zhe Chen; Sisi Yang; Yu Wang; Lifang Yu; Bicheng Zhang; Zhiguo Rao; Jianfei Gao; Shenghao Tu
Journal:  Exp Ther Med       Date:  2012-05-03       Impact factor: 2.447

9.  Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy.

Authors:  Norihiro Nishimoto; Nobuyuki Miyasaka; Kazuhiko Yamamoto; Shinichi Kawai; Tsutomu Takeuchi; Junichi Azuma; Tadamitsu Kishimoto
Journal:  Mod Rheumatol       Date:  2008-11-01       Impact factor: 3.023

10.  The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trial.

Authors:  M Schiff; C Pritchard; J E Huffstutter; V Rodriguez-Valverde; P Durez; X Zhou; T Li; K Bahrt; S Kelly; M Le Bars; M C Genovese
Journal:  Ann Rheum Dis       Date:  2008-12-15       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.